Brought to you by 
Mallinckrodt acquires skin substitute company Stratatech
08 Sep 2020
Executive Summary
Mallinckrodt PLC acquired privately held regenerative medicine company Stratatech Corp. (cell-based skin substitute). Stratatech's progenitor keratinocyte (the predominant cell type in the skin's outermost layer, the epidermis) tissue-engineering technology produces living tissues designed to mimic human skin and promote tissue regeneration.
Deal Industry
- Medical Devices
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Medical Devices
- Biomaterials
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Mallinckrodt acquires skin substitute company Stratatech
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice